ENXTBR:ARGXBiotechs
argenx (ENXTBR:ARGX) Following Strong H1 Results Looks Pricey Under The Leading Narrative
argenx (ENXTBR:ARGX) is back in focus after reporting half year 2026 earnings, with revenue of US$2.854b and net income of US$838m, supported by VYVGART and its expanded generalized myasthenia gravis reach.
See our latest analysis for argenx.
argenx's recent half year earnings and VYVGART label expansion have coincided with building momentum, with a 20.74% 90 day share price return and a 59.60% 1 year total shareholder return from a €804.4 share price today.
If you are interested in other...